

1 **A Phase II/III, Randomized, double-blind, placebo-controlled trial to evaluate**
2 **Immunogenicity and Safety of the Gam-COVID-Vac combined vector vaccine in the**
3 **prophylactic Treatment for SARS-CoV-2 infection in the United Arab Emirates**

4 **Ahmed AK. Al Hammadi^{*1,2,3}, Amna H. Alzaabi¹, Haneen B. Choker¹, Ahmed A. Ibrahim¹,**
5 **Asma Bin Ishaq¹, Ahmed E. Mahboub¹, Reem S. Al Dhaheer¹, Mohamed N. Alzaabi¹,**
6 **Timothy A. Collyns⁴, Gehad ElGhazali^{5,6}, Stefan Weber^{5,6}, Basel K. al-Ramadi^{*7,8,9}**

7

8 ¹ Tawam Hospital, Al Ain, Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United
9 Arab Emirates

10 ² President, Emirates Infectious Disease Society, Emirates Medical Association, Dubai, United
11 Arab Emirates

12 ³ Department of Internal Medicine, College of Medicine and Health Sciences, United Arab
13 Emirates University, Al Ain, Abu Dhabi, United Arab Emirates

14 ⁴ Tawam Hospital, Purelab, Purehealth, Al Ain, Abu Dhabi, United Arab Emirates

15 ⁵ Sheikh Khalifa Medical City, Purelab, Purehealth, Abu Dhabi, United Arab Emirates

16 ⁶ Department of Microbiology, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates

17 ⁷ Department of Medical Microbiology & Immunology, College of Medicine and Health Sciences,
18 United Arab Emirates University, Al Ain, Abu Dhabi, United Arab Emirates

19 ⁸ Zayed Center for Health Sciences, United Arab Emirates University (UAEU), Al Ain, UAE

20 ⁹ ASPIRE Precision Medicine Research Institute Abu Dhabi, United Arab Emirates University, Al
21 Ain, United Arab Emirates.

22
23 * Correspondence

24 *Ahmed AK Al Hammadi
25 ahhammadi@seha.ae

26

27 *Basel K. al-Ramadi

28 Ramadi.b@uaeu.ac.ae

29

30 **Keywords:** COVID-19, randomized control trial, vector, adenoviral vector vaccine, Sputnik V

31 **Abstract**

32 **Background:**

33 Different platforms were used to develop vaccines against SARS-CoV-2 which were
34 instrumental in bringing an end to the pandemic. Nevertheless, long term efficacy and safety
35 profiles of the various vaccine types is still being investigated. The current trial aimed to assess
36 the safety and immunogenicity of the Gam-COVID-Vac combined vector vaccine against SARS-
37 CoV-2-induced coronavirus infection up to 6 months post vaccination.

38 **Methods:**

39 In this randomized, double-blind, placebo-controlled trial, study participants ≥ 18 years of age
40 with no prior SARS-COV-2 infection or vaccination were randomized (3:1) to receive the
41 heterologous recombinant human adenovirus-vectored vaccines serotypes 26 and 5 or placebo.
42 Immunogenicity was determined based on quantitative IgG antibodies (Abs) to viral S and N
43 proteins, virus-neutralizing Abs (VNA), seroconversion rates, and S protein-specific CD4 and
44 CD8 T cell responses.

45 **Results:**

46 A total of 990 participants were randomized to the vaccine (n=74) and placebo (n=246) groups.
47 Overall incidence of Adverse events (AEs) was 1844 (81.5%) in the vaccine and 501 in placebo
48 (82.1%) groups, the majority being in the mild/moderate categories. Two doses of vaccine
49 induced VNA in 100% of participants on Day 42, with geometric mean ratio (GMR) reaching
50 maximum at 120 days with average 24.14 ($p < 0.001$). Vaccine group showed a very significant
51 GMR for quantitative IgG to S protein. Difference in seroconversion rates was also significant
52 with 90.0%, 83.7% and 78.9% on days 42, 120 and 180 ($p < 0.001$ at all three points). A
53 significant rise in the median of S protein-specific CD4⁺ and CD8⁺ T-lymphocytes with a robust

54 IFN- γ response was evident after 28 days compared to baseline. Long-term follow-up
55 demonstrated persistent and significant CD8⁺ T cell and IFN- γ responses at 120 days (p=0.049
56 and 0.039, respectively) compared to placebo group.

57 **Conclusion:**

58 Gam-COVID-Vac vaccine showed a good safety profile and induced strong and durable
59 humoral and cellular immune responses. The viral-specific CD8⁺ T cell response appears to be
60 more durable following vaccination than CD4⁺ T cell counterpart. Importantly, there was no
61 evidence of any severe or persistent AEs in vaccinees suggestive of long COVID syndrome,
62 emphasizing the safety of this heterologous prime-boost vaccine.

63 INTRODUCTION

64 Coronavirus disease 2019 (COVID-19) is an emerging respiratory infectious disease caused by
65 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that infected
66 776,007,137 confirmed cases of COVID-19 and caused 7,059,612 deaths globally by August
67 18, 2024, as reported by the WHO (1). As of 26 November 2023, a total of 13.64 billion vaccine
68 doses have been administered worldwide (1). There are currently 382 COVID-19 candidate
69 vaccines in development worldwide. Out of the 382 candidate vaccines, 183 vaccines are in the
70 clinical development phase (including 50 at phase III) (2). The phase III vaccine candidates
71 include a variety of vaccine platforms such as viral vector vaccines, mRNA vaccines, inactivated
72 vaccines, protein-subunit, DNA vaccines, virus like particle, live attenuated viruses, bacterial
73 antigen-spore expression vectors, and viral vector + antigen presenting cells (2). Viral vector
74 vaccines have shown efficacy in the prevention of COVID-19 infection by 68% (95% CI) and
75 reduction in mortality with a risk ratio of 0.25 (95% CI) (3).

76 The Gam-COVID-Vac Vaccine:

77 Recombinant replication-deficient adenovirus (rAd)-based vaccines have characteristics that
78 render them potential candidates for the WHO target product profiles for long-term protection of
79 individuals at high risk of COVID-19 in outbreak settings since they promote a quick onset of
80 protective immunity (4). Moreover, the use of a 2-dose immunization regimen is believed to
81 provide a durable and long-lasting immune response (5). Prime-boost heterologous vaccination
82 with two different vectors enables the minimization of the attenuation effect that adenoviral vectors
83 may have on immune responses against the vector's components (5, 6). Therefore, based on
84 available evidence, the heterologous prime-boost vaccination approach appears to be the most
85 efficient approach for eliciting a potent and durable immune response that is independent of the
86 existence of an immune response to the vector (7).

87 The results of an interim analysis of a phase III trial involving 22,000 volunteers and using the
88 Gam-COVID-Vac vaccine, which was carried out at a median follow-up period of 48 days post
89 first dose, indicated an efficacy of 91.6% (95% CI 85.6–95.2) against COVID-19 infection (8). A
90 recent meta-analysis reported that the viral vector vaccine, Gam-COVID-Vac, was likely
91 superior to inactivated vaccines, protein-subunit vaccines, and mRNA vaccines in preventing
92 symptomatic COVID-19 and reducing mortality (9). Randomized clinical trials that have been
93 published indicate that viral vector vaccinations do not appear to increase the likelihood of
94 serious adverse events (9).

95 Aim of the study:

96 The ultimate aim of worldwide R&D is to fast-track the availability of universally safe and
97 effective vaccines. In our study, the combined vector vaccine, Gam-COVID-Vac (Sputnik V
98 COVID-19 vaccine), was developed based on rAd type 26 (rAd26) and rAd type 5 (rAd5), both
99 of which carry the gene for SARS-CoV-2 full-length glycoprotein S (rAd26-S and rAd5-S). The
100 rAd26-S and rAd5-S doses are administered intramuscularly separately with a 21-day interval.
101 The use of two varying serotypes given 21 days apart is aimed at mitigating any existing
102 adenovirus immunity in the population (10). The aim of this study was to evaluate the
103 immunogenicity and safety of the Gam-COVID-Vac combined vector vaccine in the prophylactic
104 treatment for SARS-CoV-2 infection in the United Arab Emirates (UAE) (11). The study in the
105 UAE has a distinctly different ethnic distribution. Moreover, while the original Russian study, as
106 published in the interim analysis of 22,000 volunteers, assessed cellular immunity only 28 days
107 after the first dose, our study extended this evaluation to day 120 after the first dose, offering an
108 additional 92 days of data.

109 **METHODS**

110 **Study design and participants**

111 A randomized, phase II/III, double-blind, placebo-controlled trial was conducted from December
112 2020 through August 2021 to evaluate the immunogenicity and safety of the Gam-COVID-Vac
113 combined vector vaccine (Sputnik V) in prophylactic treatment for SARS-CoV-2 infection. The
114 study included participants aged at least 18 years, with negative SARS-CoV-2 PCR and IgG and
115 IgM tests, no infectious diseases in the 14 days before enrolment. Written informed consent was
116 obtained from each participant before screening. Screening procedure included physical
117 examination wherein the medical history, concomitant medication, demographic, and
118 anthropometric data were collected; and the relevant vital functions were assessed (e.g., blood
119 pressure, heart rate, and axillar temperature). Participants were assessed by their risk category
120 of contracting the COVID-19 infection (high, medium, and general) and underwent laboratory
121 testing: complete blood count and biochemistry, COVID-19 diagnostics (PCR, qualitative IgM/IgG
122 ELISA) and urine testing for drugs, alcohol, and pregnancy (in women). Volunteers participants
123 were considered eligible if they were deemed healthy after screening procedures, had no history
124 of COVID-19 or prior contact with patients with COVID-19 within 14 days of participation in the
125 study, did not receive any other vaccinations, had not undergone therapy with steroids,
126 immunoglobulins, or any other blood-derived products within 30 days, had not consumed any
127 immunosuppressive drugs 30 days before vaccination and had no allergy to immunobiological
128 preparations including any vaccine component. The trial was approved by the UAE Department
129 of Health Central Ethics Committee, acting as the Local Ethics Committee (LEC; permission
130 number DOH/CVDC/2020/2256 dated November 11, 2020), and the UAE Ministry of Health;
131 Regulatory Committee at Ministry of Health and Prevention (RCMOHAP) permission: No. DSS-
132 AOM-52/AMD001 dated December 14, 2020. The trial is registered with ClinicalTrials.gov

133 ([NCT04656613](#)). The study is authorized and approved to be published by Human Vaccine LLC
134 and Russian Ministry of Healthcare FGBU N.F. Gamaleya Scientific Research Center of
135 Epidemiology and Microbiology.

136 **Procedures**

137 The vaccine comprises Component I (Dose 1) consisting of recombinant adenovirus serotype
138 26 particles containing the SARS-CoV-2 protein S gene and Component II (Dose 2) containing
139 recombinant adenovirus serotype 5 particles with SARS-CoV-2 protein S gene. The vaccine
140 was manufactured as a liquid formulation containing 1×10^{11} viral particles (vp) per 0.5 ml / dose.
141 In this phase II/III clinical trial, participants were randomized to a 1:3 ratio, with 250 participants
142 assigned to the placebo group and 750 assigned to the vaccine group. All investigators,
143 participants, and study staff were masked to group assignment. All randomized participants
144 signed informed consent. After randomization, 8 participants were excluded. After exclusion,
145 745 remained at the end of the study of which 744 subjects took the second dose of the vaccine
146 while 246 subjects took the second dose as placebo.

147 The calculated therapeutic dose of $1.0 \pm 0.5 \times 10^{11}$ v.p. was administrated intramuscularly into
148 the deltoid muscle of the shoulder, two times on Day 1 and Day 21 and were assessed for
149 safety, reactogenicity and immunogenicity over the whole period of investigation (180 days).

150 Screening procedure began after the informed consent form was signed by the participants, or
151 legal representative, and lasted no more than 7 days before a participant was determined as
152 eligible and included in the study. Participants underwent physical examination at screening, on
153 vaccination day (day 1 and Day 21) and on follow up days 28, 42, 120 and 180. During the
154 observation visits, vitals were assessed in all enrolled participants, and changes in the
155 participants' condition and wellbeing compared to the previous visit were recorded. In addition,

156 Adverse events were collected and reported via the weekly and biweekly Follow Up Tele-
157 consultation/Phone calls with the participants over all the observation period up to day 180.
158 Blood (complete blood count, Total Antibodies to SARS-COV-2, Alanine aminotransferase
159 (ALT), Alkaline phosphatase (ALP), Aspartate aminotransferase (AST), Albumin, Total protein
160 (TP), Total Bilirubin, Direct Bilirubin, Prothrombin time (PT), Random Glucose Blood Level,
161 Calcium, Potassium, Bicarbonate (Total CO₂), Chloride, Blood Urea Nitrogen (BUN), Creatinine
162 and Alcohol Level were performed at the initial screening. All participants were also tested for
163 hepatitis B and C, HIV and syphilis once during the screening visit. Urine analysis (pH, clarity,
164 protein, glucose, ketones, cellular content, crystals, pregnancy) was performed three times over
165 all the study period, at the screening, before the vaccine injection on day 1 and on day 21. The
166 following immune parameters were assessed: Virus-neutralizing activity (VNA), Quantitative IgG
167 antibodies to S-protein, Qualitative IgG to N-protein, CD4 and CD8 T-cell proliferation response
168 to S-protein, and IFN- γ recall response to S-protein. Quantitative IgG antibodies to S-protein,
169 Qualitative IgG to N-protein and Serum neutralizing activity were assessed at four different time
170 points of the study period: prior to immunization on day 1 and on days 42, 120 and 180 after
171 immunization. For the evaluation of cell-mediated immune responses, CD4 and CD8 T-cell
172 proliferation and IFN- γ response to S-protein were carried out prior to immunization on day 1
173 and on days 28 and 120 after immunization (3 time points). Biological material was collected for
174 SARS-CoV-2 and tested using PCR on screening visit and prior to the immunization on day 21
175 (2 times).

176 **Sample size calculation and justification.** Based on published data, antibody titers in the
177 patients who recovered from COVID-19 become GMT IgG 2974.83 in >21 days (12). Sample
178 size estimation was calculated for a repeated measures ANOVA using the G*Power software
179 (Version 3.1.9.2). Since the estimated effect size is 0.12, for the purpose of this study a
180 significance level of 5% ($\alpha = 0.05$), and power of 90% are used. The design will adopt an
181 unbalanced design of the placebo and vaccinated group of a 1:3 ratio. Normalizing the number
182 of recruited subjects by 30% for adverse events and dropouts (732×1.3) the total number of
183 subjects that will be recruited will be 1000 (250 subjects in the placebo group and 750 in the
184 vaccinated group). Sample sizes were selected to balance statistical power and recruitment
185 feasibility.

186 **Outcomes**

187 The primary outcome measures for immunogenicity were measurement of the change from
188 baseline of antibody levels specific to SARS-CoV-2 glycoprotein S on days 1 (before the first
189 vaccine dose) and on days 42, 120 and 180 after first dose of vaccination; changes in SARS-
190 CoV-2 neutralizing antibody titers at the same time points; and determination of CD4⁺ and CD8⁺
191 T-cell responses and IFN- γ production after recall stimulation with viral S protein on day 1 (prior
192 to vaccine administration) and days 28 and 120 following vaccination. Changes in the level of
193 antibodies against SARS-CoV-2 N-protein were also determined. Secondary outcome measure
194 was safety of the “Sputnik V” Vaccine. Outcome measures for safety were the number and
195 severity of adverse events during the whole study after injection of the first dose of the vaccine.

196 **Statistical analysis**

197 Statistical data processing used the SPSS version 24 software (IBM Corp. Released 2016. IBM
198 SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp.) and GraphPad Prism 10

199 (One-way ANOVA followed by Dunnett's multiple comparisons test was performed using
200 GraphPad Prism version 10.0.0 for Windows, GraphPad Software, Boston, Massachusetts USA,
201 www.graphpad.com) software application package. The statistical analysis of immunogenicity
202 included all the participants who have completed the study as per protocol. The safety analysis
203 included all the participants who had received a dose of the study vaccine. No replacement of
204 missing, unanalyzable or doubtful data has been envisaged. The geometric mean concentrations
205 of the Quantitative IgG antibodies to S and N Protein and virus-neutralizing antibodies in trial
206 participants were computed as the exponential of the mean of the log-transformed concentrations
207 and its 95% confidence interval was reported. The log-transformed concentrations were
208 compared between the two study arms using the independent Student's t-test at 42 ± 4 , at 120 ± 14
209 and at 180 ± 14 days after the first dose. Geometric mean ratios were calculated along with their
210 95% confidence Interval. The percentage of participants with 4-fold or more increase in the
211 concentrations of Quantitative IgG antibodies to S and N Protein in trial subjects on the drug
212 administration day before injecting the first dose of the study vaccine/placebo and on 42 ± 4 days
213 after the first dose was computed along with their 95% confidence intervals using the Wald
214 Method or the Clopper-Person methods if needed (when at least one observed cell count is below
215 5). Differences between the two study arms were compared using the Chi-squared test. Cellular
216 immune response levels were summarized using medians 25th (Q1) and 75th (Q3) quartiles
217 values. Levels of IFN- γ that were below the limit of detection were replaced by the border limit of
218 detection to be able to compute the mathematical measures in both arms. The change in the
219 concentrations of IFN- γ and the extent of proliferative CD4⁺ and CD8⁺ T cell responses between
220 participants in the two study groups were analyzed using the Wilcoxon-Mann-Whitney test (or the
221 t-test on the log-transformed endpoints) at days 28 ± 4 days and at 120 ± 14 days after the first dose
222 using GraphPad Prism 10.0 (San Diego, CA, USA). Increases in those variables within each study
223 arm were tested using the Wilcoxon signed-rank test at the specified time points. The safety

224 analysis included all participants who had received the study vaccine/ placebo injection and for
225 whom all available data were verified in the case report form at the time of database lock. Adverse
226 events were coded using MedDRA, version 24.0. Adverse events were presented by group,
227 system organ and class, and preferred term. AE severity and causality have been assessed by a
228 physician investigator. The results of laboratory examinations, vital signs, and other safety
229 parameters are provided descriptively.

230 RESULTS

231 Study Participants

232 A total of 2239 participants were screened, out of which 1239 (55.3%) were excluded due to
233 eligibility criteria. The remaining 1000 (44.6%) were enrolled and randomized on a 1:3 ratio with
234 750 assigned to the vaccine group and 250 to placebo. The demographic characteristics of the
235 enrolled study participants are summarized in **Table I**. It is also worth noting the wide ethnic
236 distribution of the participants in this study, which was as follows: South-East Asia 48.7%,
237 MENA region 36.5%, Central/South America 9%, Africa 3.7%, and Europe 2.1%. This
238 distribution is unique to the UAE. After randomization, 8 participants were excluded (5 subjects
239 from the vaccine arm and 3 from the placebo) for not meeting eligibility criteria. The reasons for
240 exclusion were early withdrawal due to asthma (n=3), pregnancy (n=1), positive PCR (n=2),
241 positive IgM/IgG for SARS COV2 (n=1), or active tuberculosis (n=1). After exclusion, 745
242 remained of which 744 subjects took the second dose of the vaccine. Similarly, out of the
243 remaining 247 subjects in the placebo group, 246 took the second dose. For the
244 immunogenicity data, 17 (2.3%) were missed from the vaccine arm versus 10 (4.0%) from the
245 placebo arm. The main reasons for withdrawal were either loss to follow-up or not attendance of
246 the visit. Finally, 78 subjects were included in the cell-mediated study in the vaccine group
247 versus 22 in the placebo at baseline. Six subjects didn't attend the test at 28 days yielding a
248 total 94 individuals with available data while 10 more subjects were absent at 120 days yielding
249 a final total of 84 individuals. Full details are presented in **Figure 1**.

250

251 Overall incidence of AEs in the vaccine group was 1844 versus 501 in the placebo group. Most
252 of the recorded AEs in the vaccine arm were either mild (n=460; 61.8%), or moderate (n=99;
253 13.3%); only 6.2% (n=46) were severe AEs. Similarly, in the placebo group, most reported AEs

254 were either mild (n=160; 65.0%) or moderate (n=26; 10.6%), with only 6.5% (n=16) reporting
255 severe AEs. No death was reported in either arm. Four serious adverse events were reported in
256 the placebo arm after 42 days while five serious adverse events were reported after 120 days.
257 At day 120 post vaccination, the majority of subjects reported mild intensity events, 307 (41.2%)
258 in vaccine group and 90 (36.6%) in placebo group, Moderate intensity events were reported by
259 38 subjects (5.1%) in vaccine group and 18 subjects (7.3%) in placebo group. Few subjects
260 reported severe intensity events, 7 (0.94%) in vaccine group and 3 (1.2%) in placebo group.
261 Finally, one potential life-threatening event was reported by a subject from the placebo group.
262 Details of AEs in total or following each vaccine dose are presented in **Tables II, III and IV**.
263 Overall, only a few events were determined to be related to the investigational medicinal product
264 after 120 days (44 events in vaccine group and 13 events in the placebo group). **Table V** shows
265 more details about the relatedness of AEs to the medicinal product.

266 AEs were further extensively described in terms of events occurrence according to the MedDRA
267 coding system. At the day 42 time point, most of AEs among both the vaccine and placebo groups
268 were general disorders and administration site conditions such as increased temperature and
269 administration site pain. Increased temperature occurred in 47.7% (n=355) of the vaccine group
270 versus 49.6% (n=122) in the placebo arm. Administration site pain reported by 20.9% (n=156)
271 versus 5.4% (n=14), respectively. Vascular disorders such as systolic hypertension occurred in
272 22.0% (n=164) in the vaccine versus 25.2% (n=62) in the placebo group. Nervous system
273 disorders such as headache occurred in 19.1% (n=142) and 12.2% (n=30), respectively. After
274 120 days, the main AEs were high temperature (11.7% in vaccine vs. 11.8% in placebo arm) and
275 fever (4.0% vs. 7.7%, respectively). Systolic hypertension occurred in 4.0% vs. 4.5% in the
276 vaccine and placebo groups. Viral infections, such as COVID-19, occurred in 9.3% (n=69) and
277 11.0% (n=27), respectively. After 180 days, 92 participants tested positive for COVID-19 infection,
278 62 (8.3%) in the vaccine and 30 (12.2%) in the placebo arms.

279 Serious AEs (SAEs) were reported only in the placebo arm at 42 days. One subject reported
280 tachypnea as a respiratory disorder and it was related to COVID-19 infection; another subject
281 reported COVID 19 infection, a third subject reported influenza and a fourth had an elevated
282 alanine transferase level (**Table VI**). After 120 days, 3 SAEs were reported in each of the
283 groups. In the placebo arm, a subject reported a lymphoma, another subject reported COVID-19
284 infection while the third subject reported a hemorrhoidectomy. In the vaccine group, one subject
285 reported back pain, a second reported a maculopapular rash, while a third subject reported
286 chronic cholecystitis (**Table VI**).

287 The immunogenicity assessment demonstrated that the vaccine induced an immune response
288 in participants. Sera for detection of SARS-CoV-2 -specific IgG antibodies to S and N Proteins
289 were collected before immunization (on day 1), and at days 42, 120 and 180 after the first dose
290 of vaccine/placebo administration. At baseline, both vaccine and placebo groups had similar
291 levels of IgG antibodies to S protein, with geometric mean (GM) plus 95% confidence interval
292 (CI) of 1.232 (1.155-1.316) for placebo and 1.236 (1.18-1.294) for the vaccine group ($p =$
293 0.346). After 42 days, the GM 95%CI was 89.29 (85.46-93.29) for the vaccine group and 1.729
294 (1.486-2.012) for placebo ($p < 0.0001$). The same trend was also evident at 120 days, with an
295 average of 46.1 for vaccine group and 1.91 for placebo group, and at day 180 showing an
296 average of 30.9 for vaccine group and 2.09 for the placebo group, with the differences being
297 highly significant at both time points (**Figure 2A**). In sharp contrast, IgG antibodies to the viral N
298 protein were not evident in either the vaccine or the placebo group. Both groups had similar
299 antibody concentrations, with GM and 95% confidence interval (CI) of 0.03 (0.029-0.032) for
300 vaccine and 0.03 (0.029-0.038) for the placebo arm ($p=0.212$). After 42 days, the GM 95%CI
301 was 0.039 (0.036-0.0432) and 0.045 (0.038-0.054) for the vaccine and placebo groups,
302 respectively ($p=0.27$). This trend was also observed at days 120 and 180 (difference was also
303 nonsignificant at both dates) (**Figure 2B**).

304 Seroconversion, defined as a 4-fold increase in quantitative S protein-specific IgG, was
305 calculated at baseline and in days 42, 120 and 180. Seroconversion was zero at baseline with
306 95% confidence between (zero and 0.005%) for both arms. After 42 days, the vaccine group
307 had a seroconversion rate (95%CI) of 99.3% (98.4%-99.8%) while the rate in placebo group
308 was 9.4% (6.0%-13.8%), a difference that was highly significant ($p<0.001$). The unadjusted
309 difference in rate attributed to the vaccine was 90.0%. Similarly, the 4-fold increase was
310 maintained in the vaccine arm at days 120 and 180 with seroconversion rates of 97.1% (95.5%-
311 98.3%) and 94.7% (92.3%-96.5%), respectively. The unadjusted difference in rate versus the
312 placebo was 83.7% at 120 days and 78.9% at 180 days, with significant p-values ($p<0.001$)
313 **(Figure 3)**.

314 Neutralizing antibodies to SARS-CoV-2 were determined in vaccine and placebo arms at
315 baseline and at days 42, 120 and 180 post vaccination **(Figure 2C)**. Geometric mean titers of
316 neutralizing antibodies showed similar titers at baseline, 0.565 (0.392-0.812) and 0.595 (0.483-
317 0.734) for placebo and vaccine arm, respectively ($p=0.186$). The levels of neutralizing
318 antibodies increased after immunization, reaching 70.7 (67.49-74.16) (GM with 95%CI) in
319 vaccine group and 3.24 (2.441-4.311) in placebo arm after 42 days ($p<0.0001$). After 120 days,
320 GM dropped to 38.39 (35.41-41.63) in vaccine group and 0.352 (0.225-0.553) in the placebo
321 arm ($p<0.0001$). The difference between the two groups was also significant ($p<0.0001$) at day
322 180, with a GM of 24.23 (21.36-27.49) for vaccine group and 0.415 (0.245-0.704) for placebo
323 group **(Figure 2C)**.

324 Neutralizing antibodies were also compared between the two study arms of convalescents. A
325 total of 17 subjects (Vaccine group=9 and Placebo group = 8) contracted COVID-19 infection
326 during the study duration until day 42. At baseline, GM 95%CI was 1.99 (1.03-3.89) in the
327 vaccine group and 2.45 (1.08-5.62) in the placebo group. Geometric mean titers of neutralizing

328 antibodies (GM 95%CI) increased after immunization reaching 89.13 (79.43-100) in the vaccine
329 group and 53.70 (36.30-77.62) in the placebo group ($p < 0.008$) at day 42. This indicates the
330 significantly elevated titers of neutralizing antibodies in the vaccinated participants compared to
331 unvaccinated individuals following SARS-CoV-2 exposure.

332 The cell-mediated response was evaluated in a randomly selected cohort of 98 participants
333 representing the vaccine ($n=78$) and placebo ($n=20$) groups on day 1 (before the priming
334 vaccination). The number of participants decreased to 94 participants (vaccine group $n=74$;
335 placebo $n=20$) on day 28 (7 days after the booster vaccination) and 84 participants (vaccine
336 group $n=66$; placebo $n=18$) on day 120 after the priming vaccination. T cell responses were
337 determined by measuring IFN- γ secretion in cultures of peripheral blood mononuclear cells
338 (PBMCs) after recall stimulation with SARS-CoV-2 S glycoprotein (**Figure 4**). Levels of IFN- γ at
339 baseline were similar for the vaccine group (median 3.04 pg/mL [IQR 2.0-6.15]) and the placebo
340 group (median 2.08 pg/mL [IQR 2.0-6.72]) with a non-significant difference ($p=0.241$). After 28
341 days, PBMCs of participants in the vaccine group secreted substantially higher levels of IFN- γ
342 after restimulation (median 94.01 pg/mL [IQR 50.28-211.6]), which was significantly different
343 ($p=0.003$) in comparison with the placebo group (median 10.55 pg/mL [IQR 2.69-26.65]). The
344 day 28 response of the vaccine group was also significantly different ($p < 0.0001$) compared to
345 that on day 1, the day of administration of the first dose (**Figure 4**). Importantly, T cell recall
346 responses were still evident after 120 days in the vaccine group (median 61.87 pg/mL [IQR
347 12.85-210.5]) compared to the placebo group (median 12.94 pg/mL [IQR 4.83-50.56])
348 ($p < 0.039$). The day 120 response of the vaccine group was still significantly different (p
349 < 0.0001) compared to the day 1 response but was not significantly different from the day 28
350 response ($p=0.114$).

351 In order to assess the level of cell mediated immune responses in a T cell type-specific manner,
352 we measured the extent of cell proliferation in response to antigen-stimulation in both T-helper
353 (CD4⁺) and T-cytotoxic (CD8⁺) cells by flow cytometry. Cellular immune responses showed
354 proliferation of antigen-specific cells of both CD4⁺ and CD8⁺ T cells in response to glycoprotein
355 S, particularly on day 28 (**Figure 5**). The CD4⁺ T cell responses of the placebo and vaccine
356 groups at day 1 were at baseline with no significant difference between them ($p=0.433$). The
357 CD4⁺ T helper response at day 28 reached a median proliferation of 0.14% [IQR 0.01-0.325] in
358 the vaccine group compared to a median of 0.02% [IQR 0.01-0.07]) in the placebo group
359 ($p=0.0014$) (**Figure 5A-B**). Similarly, there was a significant enhancement in the antigen-driven
360 proliferation of CD4⁺ T cells on day 28 compared to day 1 of the vaccine group, the latter having
361 a median of 0.035% [IQR 0.01-0.182] ($p=0.007$). Interestingly, the CD4⁺ T cell proliferative
362 response weakened considerably by day 120, reaching a median of 0.09% [IQR 0.01-0.285],
363 that had no statistical significance compared to day 1 responses ($p=0.097$) (**Figure 5B**). In
364 contrast, the CD8⁺ T cell proliferative response in vaccinated individuals was significantly
365 elevated on day 28 (median 0.1% [IQR 0.01-0.23]) ($p=0.022$) and day 120 (median 0.11% [IQR
366 0.01-0.3]) ($p=0.001$) compared to day 1 (**Figure 5C-D**), suggesting that the S protein-specific
367 CD8 T cell response is more durable following vaccination than the CD4 T cell response. One
368 noticeable finding in the placebo participants was the apparent rise in CD8 T cell response
369 observed at day 120 (median 0.085 % [IQR 0.01-0.255]) compared to day 1 ($p=0.038$). This is
370 most likely due to natural exposure to SARS-CoV-2 virus in the community. In fact, at least 2 of
371 the 20 participants in the placebo group had evidence of positive PCR tests for the virus
372 between days 28 and 120 of the trial.

373 **DISCUSSION**

374 In this study, we report the findings on the safety and immunogenicity of Gam-COVID-Vac
375 evaluation from analysis of this phase II/III clinical trial conducted in the UAE. The vaccine
376 efficacy was consistent with previous studies of Sputnik-V vaccine in other populations (8,
377 13)(14). Our findings show that the vaccine was well tolerated, with only 0.4% of participants in
378 the vaccine group reporting serious adverse events, all of which were considered to be
379 unrelated to the vaccine. No deaths were reported. The data show that revaccination may cause
380 milder adverse events compared to first dose of immunization against COVID-19. The AEs
381 observed after the two doses and after 120 days of the study vaccine are typical reactions to
382 most types of vaccines, with the great majority being in the mild/moderate categories, including
383 general disorders and administration site conditions. The COVID-19 case incidence among the
384 vaccine and placebo groups was 62 (8.3%) versus 30 (12.1%), respectively, showing a partially
385 protective effect after a two-dose immunization; however, the study design does not allow us to
386 draw conclusions from these observations. Of note, the observed adverse effects using the
387 Sputnik V vaccine are milder than those observed using the ChAdOx1-S nCoV-19 or mRNA
388 vaccines. According to published reports, serious thrombosis with thrombocytopenia syndrome
389 (TTS) mediated by platelet-activating antibodies against platelet factor 4 (PF4), which clinically
390 mimics autoimmune heparin-induced thrombocytopenia, were reported following the ChAdOx1-
391 S nCoV-19 vaccine (15). Those symptoms were similar to those observed in patients
392 developing Long COVID following infection. Moreover, recent evidence has suggested that
393 mRNA vaccines may induce persistent, and, in some cases, severe adverse effects in a small
394 percentage of individuals (16). No symptoms of long COVID were reported by the nearly 1000
395 participants in our study.

396 The immunogenicity of the Gam-COVID-Vac vaccine was demonstrated by the induction of
397 strong humoral and cellular immune responses (8). The level of virus neutralizing antibodies is
398 thought to be a predictive indicator of immune protection against COVID-19 but the protective
399 cutoff value remains unknown (17). In the current report, the neutralizing antibody response was
400 monitored at days 42, 120, and 180 after immunization, and the results demonstrate that the
401 sputnik V vaccine effectively induced a strong and specific humoral immune response. Two
402 injections of the Gam-COVID-Vac vaccine induce VNA in 100% of participants by day 42 after
403 immunization. The results indicated that GMR increased and reached maximum at day 120 with
404 an average of 24.14, with a significant difference between the two study arms, followed by a
405 decline at 180 days. Nevertheless, the optimal interval between injections and times of booster
406 injections remains undetermined.

407 A comparison of the convalescent serum samples after COVID-19 infection in both study arms
408 at day 42 suggests that the observed humoral immune response was likely boosted by
409 vaccination, with GMR 95%CI increasing to 89.13 in the vaccine group compared to 53.70 in the
410 placebo group (p -value <0.008). These findings indicate that the Gam-COVID-Vac vaccine is a
411 good candidate for boosting immune responses (after initial immunization or natural infection)
412 against COVID-19 used in the re-vaccination regimen.

413 There were notable significance differences in the vaccine effects on immunogenicity. On day
414 42 after immunization, the vaccine induced an increase in quantitative IgG concentration in
415 99.3% of participants. This increase was maintained in the vaccine arm at 120 and 180 days
416 with seroconversion rates of 97.1% and 94.7%, respectively. After 42 days, the GMR 95%CI
417 was 54.95 for vaccine group and 1.70 for placebo group, a difference that was highly significant,
418 and this pattern was still evident at 120 and 180 days.

419 Our findings demonstrate that a 2-dose immunization regimen with the Gam-COVID-Vac vaccine
420 resulted in the formation of anti-viral cell-mediated immune responses, as evidenced by the
421 significant rise in the median of proliferating antigen-specific CD4⁺ and CD8⁺ T-lymphocytes and
422 extent of secreted IFN- γ after vaccination as compared to baseline levels. The significant rise in
423 the percentage of proliferating antigen-specific CD4⁺ T cells was observed on day 28 following
424 the primary vaccine dose, and 7 days after the booster dose. This response appeared to decline
425 by day 120 to a non-significant level but remained marginally higher than baseline. In contrast,
426 there was a significant and persistent rise in antigen-specific CD8 T cell proliferation on day 28
427 which remained significant on day 120.

428 Recently, a study compared the neutralizing activity of sera collected from participants after
429 receiving 2 doses of the Gam-COVID-Vac vaccine (n=31) or the BNT162b2 vaccine (n=17)
430 against the omicron variant of SARS-CoV-2 (18). Serum samples were collected longitudinally
431 from 1-2 weeks up to 6 months after the second vaccine dose. The findings demonstrated that
432 the titer of neutralizing antibodies in sera of individuals after Gam-COVID-Vac vaccine persisted
433 longer than in sera of individuals given the mRNA vaccine. In general, the relative efficacy of sera
434 following the Gam-COVID-Vac vaccine was ~3-fold higher than equivalent sera from mRNA
435 vaccine group. Thus, heterologous vaccination using the Gam-COVID-Vac vaccine could be an
436 effective strategy to boost immunity against SARS-CoV-2 variants in individuals who had received
437 other forms of vaccination, including the BNT162b2 vaccine (18).

438 While Gam-COVID-Vac had an efficacy of 91.6% (85.6-95.2) to prevent severe COVID-19 after
439 the second dose (8), the single dose Ad26.COVS vaccine prevented 66.1% (55.0 to 74.8) of
440 moderate to severe COVID-19 at 28 days (19), and 2 doses of the AZD1222 (ChAdOx1 nCoV-
441 19) vaccine had 74.0% efficacy in preventing COVID-19 (65.3- 80.5) (20). In a multi-center trial,
442 the AZD1222 vaccine had an efficacy of 66.7% (57.4% to 74%) against SARS-CoV-2 (21) and

443 prevented 70.4% (43.6 to 84.5) of symptomatic alpha variant COVID-19 in the UK (22).
444 Convidecia™ Ad5-nCoV prevented 65.7% of symptomatic COVID-19 28 days after a single dose
445 and was 91% effective in treating severe disease (23).

446 Our findings concerning AEs are in line with what has been recently reported (24). The reported
447 AEs varied based on the type adenoviral-vectored vaccines. The percentage of AEs reported for
448 Gam-COVID-Vac single dose (Sputnik Light), and Gam-COVID-Vac double dose Sputnik V was
449 estimated to be 85.3% and 82.6%, respectively. Percentage AEs reported for the AZD1222
450 (AstraZeneca) vaccine tended to be higher (93.9%) and were associated with systemic
451 manifestations, including fever and headache which was reported in more than 50% of
452 participants after receiving the vaccine (21, 24).

453 In conclusion, the results of this randomized, controlled, phase II/III trial of Gam-COVID-Vac in
454 UAE demonstrate the high immunogenicity and good tolerability profile of the vaccine in
455 participants aged 18 years or older. Our study provides evidence for significant, long-term, cell-
456 mediated immune responses to the vaccine, in particular CD8⁺ T lymphocytes and IFN- γ
457 production, persisting for at least 120 days.

458 **Limitations**

459 Limitations of this study include being a single-center study with a relatively small sample size
460 compared to other international studies of phase III trials. However, this study was focused on the
461 efficacy of the Gam-COVID-Vac vaccine in the United Arab Emirates which has a unique
462 population of diverse ethnic and genetic backgrounds. Although the number of participants in the
463 study is small, the efficacy of the Gam-COVID-Vac in our cohort is in line with the interim analysis
464 of Phase III conducted on 22,000 volunteers in Russia (8). Another limitation of our study is the
465 lack of information on the neutralization of vaccine-induced sera against other SARS-CoV-2

466 variants. There is evidence that neutralization capacity of sera following vaccination with ancestral
467 S protein-containing vaccines is reduced when tested against many viral variants (25-27).
468 Nevertheless, when compared with mRNA vaccination, the relative efficacy of Gam-COVID-Vac-
469 induced sera was ~3-fold higher than equivalent sera from the mRNA vaccine group (18). It is
470 generally believed, however, that T cell immunity against viral variants is maintained, hence
471 forming the basis of continued protection against infection in humans (28, 29). Further studies of
472 candidate vaccines are needed to obtain information on the defining parameters of protection and
473 duration of post-vaccine protective immune responses.

474 **Author Contributions**

- 475 Ahmed AK. Al Hammadi: Principal Investigator. Protocol revision, approval, supervision of
476 study, data analysis, manuscript writing and final review, submission.
- 477 Amna H. Alzaabi: Sub-investigator. Subject enrolment, review and approval of final manuscript
- 478 Haneen B. Choker: Sub-investigator. Subject enrolment, review and approval of final manuscript
- 479 Ahmed A. Ibrahim: Sub-investigator. Subject enrolment, review and approval of final manuscript
- 480 Ahmed I. Mahboub: Sub-investigator. Subject enrolment, review and approval of final
481 manuscript
- 482 Reem S. Al Dhaheri: Sub-investigator. Subject enrolment, review and approval of final
483 manuscript
- 484 Mohamed N. Alzaabi: Sub-investigator. Subject enrolment, review and approval of final
485 manuscript
- 486 Timothy A. Collyns: Conduction of baseline labs, management of samples and supervision of
487 sample handling and transportation to collaborating central labs; review of final manuscript.
- 488 Gehad ElGhazali: Conduction of humoral immune testing and review of final manuscript.
- 489 Stefan Weber: Conduction of humoral immune testing and review of final manuscript.
- 490 Basel al-Ramadi: Co-Principal investigator; conduction of cellular immune testing, data
491 collection and analysis, manuscript writing and review of final manuscript.

492 **Funding**

493 The Global Sponsor (outside of United Arab Emirates): Human Vaccine LLC

494 The Local Sponsor in United Arab Emirates: Aurugulf Health Investment

495 Vaccine Development Company: Russian Ministry of Healthcare FGBU N.F. Gamaleya

496 Scientific Research Center of Epidemiology and Microbiology. The sponsors had no role in the

497 conduct of the trial or analysis of the data collected from volunteers or in the preparation of the

498 manuscript for publication. This study was also funded in part by a grant from Zayed Center for

499 Health Sciences (#31M493), Office of Research and Sponsored Projects, United Arab Emirates

500 University, to BKa-R.

501 **Acknowledgments**

502 We wish to thank our global sponsor (Human Vaccine LLC) and the local sponsor in the UAE
503 (Aurugulf Health Investment). We also wish to thank the Russian Ministry of Healthcare FGBU
504 N.F. Gamaleya Scientific Research Center of Epidemiology and Microbiology for all help
505 received to initiate the study and providing logistical support. We wish to thank the team of
506 Infectious Disease department at Tawam Hospital for their support during the study. We are
507 grateful to Dr Shoja Haneefa, Yassir Mohamed, Ashraf Al-Sbiei, Heba Taji and Ienas Idriss
508 (Department of Medical Microbiology & Immunology, College of Medicine & Health Sciences,
509 United Arab Emirates University) for performing the cell mediated immunity assays. We also
510 thank the laboratory staff at Purelab, Sheikh Khalifa Medical City-Abu Dhabi, for performing all
511 of the serological assays. We would like to thank the study participants, clinical site staff, and
512 PDC clinical research organization for their collaboration.

513 **Table I. Demographic and anthropometric characteristics of trial participants**

Variable	Vaccine (n=744)	Placebo (n=246)
Sex (n, %)		
Male	637 (85.5)	202 (82.1)
Female	107(14.5)	44 (17.9)
Age (in years) mean±SD	34.1±8.9	34.9±9.9
Race* (n, %)		
Caucasian	81 (10.9)	28 (11.4)
Asian	590 (79.3)	196 (79.7)
Black	73 (9.8)	22 (8.9)
Bodyweight, kg (mean±SD)	79.1±15.5	75.9±14.8
Height, cm (mean±SD)	171.1±8.6	170.8±8.9
Body-mass index**, kg/m ² (mean±SD)	27.0±5.0	25.9±4.3
Medical condition/Medical history (n, %)		
Yes	224 (30.1)	81 (32.9)
No	520 (69.9)	165 (67.1)
Risk of Infection***(n, %)		
High	--	-
Medium	8 (1.1)	3 (1.2)
General	733 (98.7)	243 (98.8)

514

515 * Race or ethnic group was reported by the participants

516 ** Calculation was based on the bodyweight and height measured at the time of screening.

517 *** General risk is identified that there are no additional risks related to professional activities; a medium risk is
518 identified that there is a professional contact with many people (general medical officers, social services employees,
519 shop assistants, etc.); while, a high risk means that the job involves interactions with the patients having confirmed
520 COVID-19 diagnosis.

521

522

523

Table II. Adverse events and serious adverse events frequency and percent of

524

participants

525

	42 days				120 days			
	Vaccine N=744		Placebo N=246		Vaccine N=744		Placebo N=246	
Adverse Events	Events #	No. (%) of Subjects	Events #	No. (%) of Subjects	Events #	No. (%) of Subjects	Events #	No. (%) of Subjects
Any AE	1844	606 (81.5%)	501	202 (82.1%)	697	320 (43.0%)	268	100 (40.7%)
AE* intensity								
Mild	1664	460 (61.8%)	449	160 (65.0%)	638	307 (41.3%)	232	90 (36.6%)
Moderate	119	99 (13.3%)	28	26 (10.6%)	52	38 (5.1%)	32	18 (7.3%)
Severe	60	46 (6.2%)	20	16 (6.5%)	7	7 (0.94%)	3	3 (1.2%)
Potentially life threatening	1	1 (0.1%)	-	-	-	-	1	1 (0.4%)
death	-	-	-	-	-	-	-	-
Any SAE**	-	-	4	3(1.2%)	3	3(0.4%)	2	2 (0.8%)

526

*AE=Adverse Events

527

**SAE=Severe Adverse Events

528 **Table III: Frequency of adverse / serious adverse events and percent of participants**
 529 **after first dose**

530

Adverse Events	Vaccine N=744		Placebo N=246	
	Number of events	Number (%) of subjects	Number of events	Number (%) of subjects
Any AE*	885	300 (40.3%)	233	96 (39.0%)
AE intensity				
Mild	816	232 (31.2%)	213	75 (30.5%)
Moderate	48	48 (6.5%)	12	12 (4.9%)
Severe	21	20 (2.7%)	8	8 (3.3%)
potentially life threatening	-	-	-	-
death	-	-	-	-
Any SAE**	-	-	2	2 (0.8%)

531 *AE=Adverse Events

532 **SAE=Severe Adverse Events

533 **Table IV: Frequency of adverse / serious adverse events and percent of participants after**
 534 **second dose**

535

Adverse Events	Vaccine N=744		Placebo N=246	
	Number of events	Number (%) of subjects	Number of events	Number (%) of subjects
Any AE*	965	328 (44.1%)	264	106 (43.1%)
AE intensity				
Mild	868	232 (31.2%)	240	80 (32.5%)
Moderate	63	63 (8.5%)	15	15 (6.1%)
Severe	34	33 (4.4%)	9	9 (3.7%)
Potentially life threatening	-	-	-	-
Death	-	-	-	-
Any SAE**	-	-	2	2 (0.8%)

536 *AE=Adverse Events

537 **SAE=Severe Adverse Events

538 **Table V. AE Relationship to the Investigational medicinal product**

	At 42 days						At 120 days					
	Vaccine			Placebo			Vaccine			Placebo		
		Related/Probably related			Related/Probably related			Related/Probably related			Related/Probably related	
Adverse Events	Total	Count	Percent	Total	Count	Percent	Total	Count	Percent	Total	Count	Percent
Any AE	1844	1331	72.2%	501	321	64.0%	697	44	6.3%	268	13	4.8%
AE* intensity												
Mild	1664	1214	72.9%	449	283	63.0%	638	37	5.8%	232	13	5.6%
Moderate	119	85	71.4%	28	21	75.0%	52	7	13.4%	32	0	0%
Severe	60	32	53.3%	20	14	70.0%	7	0	0%	3	0	0%
potentially life threatening	1	0	0.0%	-			-	-	-	1	0	0%
death	-	-	-	-			-	-	-	-	-	-
Any SAE**							3	0	0%	3	0	0%

539 *AE=Adverse Events

540 **SAE=Severe Adverse Events

541 **Table VI. Serious adverse events frequency and percent of participants**

542

Serious Adverse Events	Vaccine N=744		Placebo N=246		Time to Event
	No. events	No. subjects (%)	No. events	No. subjects (%)	
Respiratory disorders Tachypnoea	-		1	1 (0.4%)	42
Infectious and infestations COVID-19	-	-	2	2 (0.8%)	42 & 120
Viral Infectious Disorder Influenza	-	-	1	1 (0.4%)	42
Investigation ALT high	-	-	1	1 (0.4%)	42
Gastrointestinal therapeutic procedures Hemorrhoidectomy	-	-	1	1 (0.4%)	120
Musculoskeletal and connectivetissue disorders NEC Back pain	1	1 (0.1%)	-	-	120
Epidermal and dermal conditions Maculopapular rash	1	1 (0.1%)	-	-	120
Gallbladder disorders Chronic cholecystitis	1	1 (0.1%)	-	-	120

543

544 **Figure Legends**

545

546 **Figure 1: Profile of study participants and distribution**

547 **Figure 2.** Assessment of the humoral immune response. **(A)** Quantitative IgG to S glycoprotein
548 of SARS-CoV-2 was determined by ELISA (Euroimmun, Lübeck, Germany) on sera collected
549 from participants in the placebo (P) and vaccine (V) study arms on day 1 (before vaccination),
550 and on days 42, 120 and 180 post vaccination. **(B)** Quantitative IgG to N protein of SRAS-CoV-
551 2 was determined by chemiluminescence immunoassay (Abbott, Abbott park, IL) **(C)**.
552 Neutralizing antibodies were determined on the same four time points using sera of participants
553 from placebo and vaccine groups. The assay was carried out using general immune parameters
554 (Virus-neutralizing activity (sVNA) (GenScript Biotech, Singapore). The values for individual
555 participants and mean \pm SEM are shown in each graph. Asterisks denote statistically significant
556 differences between the indicated groups; **** ($p \leq 0.0001$).

557 **Figure 3.** Seroconversion rates in study cohorts. Determination of seroconversion rates was
558 estimated based on a 4-fold increase in the quantitative anti-S protein IgG levels for the placebo
559 and vaccine groups at each of the indicated time points. Asterisks denote statistically significant
560 differences between the indicated groups, *** ($p \leq 0.001$), calculated based on Pearson χ^2 .

561 **Figure 4.** Assessment of cell-mediated IFN- γ response to SARS-CoV-2. The extent of IFN- γ
562 production in supernatants collected after culturing peripheral blood mononuclear cells in the
563 absence (control) or presence of SARS-CoV-2 S glycoprotein (SP) for 72 hr. PBMC were
564 collected from participants of both study arms on days 1, 28 and 120 post vaccination. The
565 amount of IFN- γ in culture supernatants was determined using a human IFN- γ -specific ELISA
566 (Cat# KAP1231 from DIAsource ImmunoAssays), as per the recommendation of the
567 manufacturer. The values for individual participants and mean \pm SEM are shown. Asterisks
568 denote statistically significant differences between the indicated groups; * ($p \leq 0.05$), ** ($p \leq$
569 0.01), and **** ($p \leq 0.0001$).

570 **Figure 5.** Assessment of CD4⁺ and CD8⁺ T cell proliferative responses to SARS-CoV-2 S
571 protein. Cellular proliferation was determined following incubation of PBMCs for 72 hr with or
572 without the viral S protein using CFSE labeled cells. At the end of culture period, cells were
573 harvested, stained with monoclonal antibodies specific to CD4 or CD8 protein (Biolegend) and
574 analyzed by flow cytometry. Proliferating (with reduced CFSE staining) CD4⁺ and CD8⁺ T
575 lymphocytes were detected in the cell mixture using a BD FACSCelesta flow cytometer. The
576 values for individual participants and mean \pm SEM are shown. Asterisks denote statistically
577 significant differences between the indicated groups; * ($p \leq 0.05$), and ** ($p \leq 0.01$).





578


579 References




- 580 1. WHO. WHO COVID-19 Dashboard (2024) [updated August 18, 2024]. Available from:
581 <https://data.who.int/dashboards/covid19/cases?n=c>.
- 582 2. WHO. World Health Organization Draft landscape of COVID-19 candidate vaccines (2023)
583 [updated March 30, 2023]. Available from: [https://www.who.int/publications/m/item/draft-landscape-](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines)
584 [of-covid-19-candidate-vaccines](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines).
- 585 3. John BV, Sidney Barritt At, Moon A, Taddei TH, Kaplan DE, Dahman B, et al. Effectiveness of
586 COVID-19 Viral Vector Ad.26.COV2.S Vaccine and Comparison with mRNA Vaccines in Cirrhosis. *Clinical*
587 *gastroenterology and hepatology : the official clinical practice journal of the American*
588 *Gastroenterological Association* (2022) **20**(10):2405-8.e3. Epub 2022/06/19. doi:
589 10.1016/j.cgh.2022.05.038. PubMed PMID: 35716904; PubMed Central PMCID: PMC9212810.
- 590 4. Snook AE, Baybutt TR, Hyslop T, Waldman SA. Preclinical Evaluation of a Replication-Deficient
591 Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper
592 Epitope. *Human Gene Therapy Methods* (2016) **27**(6):238-50. doi: 10.1089/hgtb.2016.114.
- 593 5. Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov DV,
594 et al. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola
595 vaccine: An open phase I/II trial in healthy adults in Russia. *Human vaccines & immunotherapeutics*
596 (2017) **13**(3):613-20. Epub 2017/02/06. doi: 10.1080/21645515.2016.1238535. PubMed PMID:
597 28152326; PubMed Central PMCID: PMC5360131.
- 598 6. Lu S. Heterologous prime-boost vaccination. *Current opinion in immunology* (2009) **21**(3):346-
599 51. Epub 2009/06/09. doi: 10.1016/j.coi.2009.05.016. PubMed PMID: 19500964; PubMed Central
600 PMCID: PMC3743086.
- 601 7. Sapkota B, Saud B, Shrestha R, Al-Fahad D, Sah R, Shrestha S, et al. Heterologous prime-boost
602 strategies for COVID-19 vaccines. *Journal of Travel Medicine* (2022) **29**(3):taab191. doi:
603 10.1093/jtm/taab191.
- 604 8. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et
605 al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine:
606 an interim analysis of a randomised controlled phase 3 trial in Russia. *Lancet (London, England)* (2021)
607 **397**(10275):671-81. Epub 2021/02/06. doi: 10.1016/s0140-6736(21)00234-8. PubMed PMID: 33545094;
608 PubMed Central PMCID: PMC7852454.
- 609 9. Korang SK, von Rohden E, Veroniki AA, Ong G, Ngalamika O, Siddiqui F, et al. Vaccines to prevent
610 COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of
611 randomized clinical trials. *PloS one* (2022) **17**(1):e0260733. Epub 2022/01/22. doi:
612 10.1371/journal.pone.0260733. PubMed PMID: 35061702; PubMed Central PMCID: PMC8782520.
- 613 10. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, et al. International
614 seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. *Vaccine*
615 (2011) **29**(32):5203-9. Epub 2011/05/31. doi: 10.1016/j.vaccine.2011.05.025. PubMed PMID: 21619905;
616 PubMed Central PMCID: PMC3138857.
- 617 11. Alsuwaidi AR, Al Hosani FI, ElGhazali G, Al-Ramadi BK. The COVID-19 response in the United Arab
618 Emirates: challenges and opportunities. *Nature immunology* (2021) **22**(9):1066-7. Epub 2021/07/29. doi:
619 10.1038/s41590-021-01000-5. PubMed PMID: 34316063.
- 620 12. Pal M, Berhanu G, Desalegn C, Kandi V. Severe Acute Respiratory Syndrome Coronavirus-2
621 (SARS-CoV-2): An Update. *Cureus* (2020) **12**(3):e7423. Epub 2020/04/28. doi: 10.7759/cureus.7423.
622 PubMed PMID: 32337143; PubMed Central PMCID: PMC7182166.




- 623 13. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et
624 al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19
625 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. *Lancet (London,
626 England)* (2020) **396**(10255):887-97. Epub 20200904. doi: 10.1016/S0140-6736(20)31866-3. PubMed
627 PMID: 32896291; PubMed Central PMCID: PMCPMC7471804.
- 628 14. Zare H, Rezapour H, Mahmoodzadeh S, Fereidouni M. Prevalence of COVID-19 vaccines (Sputnik
629 V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran. *International
630 immunopharmacology* (2021) **101**(Pt B):108351. Epub 2021/11/22. doi: 10.1016/j.intimp.2021.108351.
631 PubMed PMID: 34801416; PubMed Central PMCID: PMCPMC8577998.
- 632 15. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic
633 Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. *The New England journal of medicine* (2021)
634 **384**(22):2092-101. Epub 2021/04/10. doi: 10.1056/NEJMoa2104840. PubMed PMID: 33835769; PubMed
635 Central PMCID: PMCPMC8095372.
- 636 16. Krumholz HM, Wu Y, Sawano M, Shah R, Zhou T, Arun AS, et al. Post-Vaccination Syndrome: A
637 Descriptive Analysis of Reported Symptoms and Patient Experiences After Covid-19 Immunization.
638 *medRxiv : the preprint server for health sciences* (2023). Epub 2023/11/21. doi:
639 10.1101/2023.11.09.23298266. PubMed PMID: 37986769; PubMed Central PMCID: PMCPMC10659483.
- 640 17. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody
641 levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature
642 medicine* (2021) **27**(7):1205-11. Epub 2021/05/19. doi: 10.1038/s41591-021-01377-8. PubMed PMID:
643 34002089.
- 644 18. Lapa D, Grousova DM, Matusali G, Meschi S, Colavita F, Bettini A, et al. Retention of Neutralizing
645 Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals. *Vaccines* (2022)
646 **10**(5). Epub 20220521. doi: 10.3390/vaccines10050817. PubMed PMID: 35632574; PubMed Central
647 PMCID: PMCPMC9144866.
- 648 19. Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, et al. Safety and Efficacy
649 of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *The New England journal of medicine* (2021)
650 **384**(23):2187-201. Epub 20210421. doi: 10.1056/NEJMoa2101544. PubMed PMID: 33882225; PubMed
651 Central PMCID: PMCPMC8220996.
- 652 20. Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al. Phase 3 Safety and
653 Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. *The New England journal of medicine* (2021)
654 **385**(25):2348-60. Epub 20210929. doi: 10.1056/NEJMoa2105290. PubMed PMID: 34587382; PubMed
655 Central PMCID: PMCPMC8522798.
- 656 21. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of
657 the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised
658 controlled trials in Brazil, South Africa, and the UK. *Lancet (London, England)* (2021) **397**(10269):99-111.
659 Epub 20201208. doi: 10.1016/S0140-6736(20)32661-1. PubMed PMID: 33306989; PubMed Central
660 PMCID: PMCPMC7723445.
- 661 22. Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al. Efficacy of ChAdOx1 nCoV-19
662 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of
663 a randomised controlled trial. *Lancet (London, England)* (2021) **397**(10282):1351-62. Epub 20210330.
664 doi: 10.1016/S0140-6736(21)00628-0. PubMed PMID: 33798499; PubMed Central PMCID:
665 PMCPMC8009612.
- 666 23. Chavda VP, Bezbaruah R, Valu D, Patel B, Kumar A, Prasad S, et al. Adenoviral Vector-Based
667 Vaccine Platform for COVID-19: Current Status. *Vaccines* (2023) **11**(2). Epub 20230213. doi:
668 10.3390/vaccines11020432. PubMed PMID: 36851309; PubMed Central PMCID: PMCPMC9965371.

- 669 24. Amer SA, Al-Zahrani A, Imam EA, Ishteiwy EM, Djelleb IF, Abdullh LR, et al. Exploring the
670 reported adverse effects of COVID-19 vaccines among vaccinated Arab populations: a multi-national
671 survey study. *Scientific Reports* (2024) **14**(1):4785. doi: 10.1038/s41598-024-54886-0.
- 672 25. Rossler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 Omicron Variant Neutralization in
673 Serum from Vaccinated and Convalescent Persons. *The New England journal of medicine* (2022)
674 **386**(7):698-700. Epub 20220112. doi: 10.1056/NEJMc2119236. PubMed PMID: 35021005; PubMed
675 Central PMCID: PMCPMC8781314.
- 676 26. Carreno JM, Alshammary H, Tcheou J, Singh G, Raskin AJ, Kawabata H, et al. Activity of
677 convalescent and vaccine serum against SARS-CoV-2 Omicron. *Nature* (2022) **602**(7898):682-8. Epub
678 20211231. doi: 10.1038/s41586-022-04399-5. PubMed PMID: 35016197.
- 679 27. Ikegame S, Siddiquey MNA, Hung CT, Haas G, Brambilla L, Oguntuyo KY, et al. Neutralizing
680 activity of Sputnik V vaccine sera against SARS-CoV-2 variants. *Nat Commun* (2021) **12**(1):4598. Epub
681 20210726. doi: 10.1038/s41467-021-24909-9. PubMed PMID: 34312390; PubMed Central PMCID:
682 PMCPMC8313705.
- 683 28. Gao Y, Cai C, Grifoni A, Muller TR, Niessl J, Olofsson A, et al. Ancestral SARS-CoV-2-specific T cells
684 cross-recognize the Omicron variant. *Nature medicine* (2022) **28**(3):472-6. Epub 20220114. doi:
685 10.1038/s41591-022-01700-x. PubMed PMID: 35042228; PubMed Central PMCID: PMCPMC8938268.
- 686 29. Liu J, Chandrashekar A, Sellers D, Barrett J, Lifton M, McMahan K, et al. Vaccines Elicit Highly
687 Cross-Reactive Cellular Immunity to the SARS-CoV-2 Omicron Variant. *medRxiv : the preprint server for*
688 *health sciences* (2022). Epub 20220103. doi: 10.1101/2022.01.02.22268634. PubMed PMID: 35018387;
689 PubMed Central PMCID: PMCPMC8750713.









Placebo

Vaccine

Day 1 Day 28 Day 120 Day 1 Day 28 Day 120

